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ABSTRACT
Genotoxic stress activates PARP1, resulting in
the post-translational modification of proteins with
poly(ADP-ribose) (PAR). We genetically deleted
PARP1 in one of the most widely used human cell
systems, i.e. HeLa cells, via TALEN-mediated gene
targeting. After comprehensive characterization of
these cells during genotoxic stress, we analyzed
structure–function relationships of PARP1 by recon-
stituting PARP1 KO cells with a series of PARP1
variants. Firstly, we verified that the PARP1\E988K
mutant exhibits mono-ADP-ribosylation activity and
we demonstrate that the PARP1\L713F mutant is
constitutively active in cells. Secondly, both mu-
tants exhibit distinct recruitment kinetics to sites of
laser-induced DNA damage, which can potentially
be attributed to non-covalent PARP1–PAR interac-
tion via several PAR binding motifs. Thirdly, both
mutants had distinct functional consequences in
cellular patho-physiology, i.e. PARP1\L713F expres-
sion triggered apoptosis, whereas PARP1\E988K re-
constitution caused a DNA-damage-induced G2 ar-
rest. Importantly, both effects could be rescued
by PARP inhibitor treatment, indicating distinct
cellular consequences of constitutive PARylation
and mono(ADP-ribosyl)ation. Finally, we demon-
strate that the cancer-associated PARP1 SNP variant
(V762A) as well as a newly identified inherited PARP1
mutation (F304L\V762A) present in a patient with pe-
diatric colorectal carcinoma exhibit altered biochem-
ical and cellular properties, thereby potentially sup-
porting human carcinogenesis. Together, we estab-
lish a novel cellular model for PARylation research,
by revealing strong structure–function relationships
of natural and artificial PARP1 variants.
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INTRODUCTION
Poly(ADP-ribosyl)ation (PARylation) is a post-
translational modification that plays key roles in cellular
physiology and stress response (1). It mainly occurs
in the nucleus and to a lesser extent in the cytoplasm.
The reaction is carried out by enzymes of the family of
poly(ADP-ribose) polymerases (PARPs), which use NAD+
to synthesize poly(ADP-ribose) (PAR), a biopolymer with
variable chain length and branching. Of the 17 members
of the human PARP gene family, at least four have been
shown to be true PARPs, i.e. these do exhibit PAR-forming
capacity, while other family members act as mono-ADP-
ribosyl transferases or are catalytically inactive. PARP1 is
a highly abundant, chromatin-associated protein that ex-
hibits PARylation activity. Upon binding to DNA damage,
in particular to strand breaks, and subsequent conforma-
tional rearrangements, PARP1 is catalytically activated
and contributes to the bulk of the cellular PAR formation
(1). This can happen either in cis by activation of a single
PARP1 molecule (2,3), or in trans, by PARP1 dimerization
at sites of DNA damage (4,5). Apart from DNA damage-
dependent activation, PARP1 activity is also regulated by
post-translational modifications, such as phosphorylation,
acetylation, and SUMOylation (6–10), as well as by direct
protein-protein interactions (11–14). Catalytic activation
leads to covalent PARylation of hundreds of target proteins
(15,16), however, PARP1 itself is the main target of its
modification (i.e. PARP1 automodification) (17,18). In
addition to covalent PARylation, PAR can interact with
proteins non-covalently via distinct PAR binding modules
(19). Importantly, PARylation is highly dynamic (20,21),
because shortly after being synthesized, PAR is rapidly
hydrolyzed by poly(ADP-ribose) glycohydrolase (PARG)
and other catabolizing enzymes (22). Thereby, PARylation
transiently modulates physico-chemical properties and
spatio-temporal activities of target proteins, including
chromatin and DNA repair factors, as well as PARPs
themselves (23,24). On the cellular level, PARylation fulfills
pleiotropic functions in genome maintenance, including
DNA repair, telomere length regulation and re-initiation
of stalled replication forks (25). Moreover, it is involved
in a host of further cell functions, such as chromatin
remodeling, transcription, epigenetics, signaling, cell cycle,
and regulation of cell death. There is also evidence that
some functions of PARP1 are independent of its enzymatic
activity, such as its action as a co-activator or repressor of
certain transcription factors (1). On the organismic level,
these functions link PARP1 and PARylation tomechanisms
of inflammation and metabolism, as well as aging and can-
cer biology (24,25). Notably, several PARP inhibitors are
currently being tested in clinical cancer therapy, either
in combination with classical chemo- or radiotherapy or
as stand-alone drugs following the concept of synthetic
lethality in BRCA1/2 deficient tumors. Recently, the PARP
inhibitor olaparib has been approved by the EMA and
FDA for the use in certain BRCA-mutated ovarian cancers
(26,27).
A lot of our knowledge on PARP1 and PARylation has
been obtained through a series of studies using three inde-
pendently generated Parp1 knock-out mouse models and
immortalized mouse embryonic fibroblasts (MEFs) derived
thereof (28–31), as well as siRNA-based knock-down ap-
proaches (32). Strikingly, a genetic double knock-out of
Parp1 and Parp2 resulted in embryonic lethality in the
mouse, thereby demonstrating a key function of PARyla-
tion during development (33). To the best of our knowledge,
besides a very recent report on a CRISPR/Cas-generated
PARP1 knock-out in HEK cells (34), genetic deletion of
PARP1 in human cancer cell lines has so far not been
described. Notably, at present no PARP1 mutations have
been directly related to human hereditable diseases – pre-
sumably because such mutations lead to embryonic lethal-
ity beforehand. Yet, several PARP1 polymorphisms exist
that have been associated with an increased risk for can-
cer development and inflammatory diseases. For example,
a PARP1 polymorphism, causing the amino acid exchange
(aa) V762A (35), leads to reduced enzymatic activity of
purified recombinant PARP1 protein (36,37). Notably, the
PARP1\V762A variant is associated with an increased risk
for the development of several types of cancers in spe-
cific ethnicities (38,39). How the V762A variant and other
potentially disease-associated PARP1 polymorphisms and
mutations affect cellular PARP1 activities and functions is
so far unknown.
Here, we report a genetic knock-out of PARP1 in one
of the most widely used human cell systems, i.e. HeLa
cells, via TALEN-mediated gene targeting. We character-
ized these cells with regards to PARylation metabolism and
genotoxic stress resistance. By reconstituting HeLa PARP1
KO cells with a series of PARP1 variants, we then analyzed
structure–function relationships of PARP1 variants in a cel-
lular environment without interfering with endogenously
expressed WT-PARP1. These variants included sets of ar-
tificial mutants and natural variants to illustrate the poten-
tial of this system for its wider usage in PARylation research.
The first set included two artificial PARP1 mutants that are
of high interest to understand the cellular biochemistry of
PARylation, i.e. a hypomorphic (E988K) and a hypermor-
phic (L713F) PARP1mutant. Using a second set of PARP1
variants, we then analyzed cellular consequences of natu-
rally occurring PARP1 variants, i.e. the PARP1 polymor-
phism leading to the V762A aa exchange and a newly iden-
tified germline PARP1 mutant (F304L) in a patient with
pediatric colorectal carcinoma (NB. in addition the patient
carried the V762A polymorphism and a pathogenic muta-
tion in BRCA2). Further, we characterized functional con-
sequences of the PARP1-reconstitution in HeLa PARP1
KO cells to improve our understanding on the significance
of PARP1 and PARylation in (patho-)physiology.
MATERIALS AND METHODS
Generation of HeLa PARP1 KO cells by TALEN-mediated
gene targeting
Cells were cultured in DMEM supplemented with 10%
FBS, 2 mM L-glutamine and 1% penicillin/streptomycin
at 37◦C, 5% CO2 and 95% humidity. TALENs were cus-
tom synthesized by Cellectis Bioresearch and were designed
to target the first exon of the PARP1 gene in close prox-
imity to the start codon (Supplementary Figure S1). For
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the generation of stable PARP1 KO cell lines, HeLa Ky-
oto cells were transfected with 1 g of each TALEN arm
DNA using Effectene transfection reagent (Qiagen). Af-
ter 24 h, cells were subcloned using a limited dilution ap-
proach. Briefly, TALEN-transfected cells were trypsinized
and diluted to a concentration of 1000 cells/ml. From this
dilution, three different sub-dilutions were prepared (100
cells/ml, 30 cells/ml, and 5 cells/ml) and each one seeded
into a 96-well plate (100 l per plate). After 5–8 days, the
plates were examined for the formation of cell colonies.
Only wells with one single colony were selected for fur-
ther processing. Clones were screened for a reduction in
PARP1 expression via immunofluorescence analysis (see
below). Two rounds of TALEN-transfection and clonal ex-
pansion were necessary to target all PARP1 alleles present
in the HeLa genome. Complete ablation of PARP1 expres-
sion in individual clones was verified by Western blotting.
The parental HeLa Kyoto cell line was used as a wild-type
(WT) control.
Orthologous expression and purification of recombinant
PARP1
Baculovirus expression constructs of PARP1 were gener-
ated according to manufacturer’s instructions (BD). Re-
combinant (rec.) PARP1 was overexpressed in Sf9 insect
cells with an MOI of 1 for 60 h. Thereafter, cells were har-
vested, pelleted and stored at−80◦C. Rec. PARP1was puri-
fied as described previously (40), withmodifications. Briefly,
cell pellets were lysed for 20 min in lysis buffer (1 ml per
1.5 × 107 cells; 25 mM Tris–HCl pH 8.0, 10 mM EDTA
pH 8.0, 50 mM glucose, 0.2% Tween 20, 0.2% NP-40, 0.5
M NaCl, 1 mM PMSF and 1 mM 2-mercaptoethanol) and
cell debris was cleared by centrifugation at 20 000× g for 20
min. Protamine sulfate (1 mg/ml) was added to the super-
natant and samples centrifuged again for 10 min at 20 000
× g. Next, ammonium sulfate was added to 30% saturation,
followed by centrifugation at 25 000 × g for 20 min. Am-
monium sulfate saturation in the supernatant was increased
to 80%, and centrifuged again at 20 000 × g for 15 min.
For desalting, the PARP1 containing pellet was dissolved
in Buffer 2 (1 ml per 1.5 × 107 cells; 100 mM Tris–HCl pH
7.4, 0.5 mMEDTA pH 7.4, 10% glycerol, 1 mMPMSF and
2 mM 2-mercaptoethanol) and loaded onto a Sephadex G-
100 column (Sigma-Aldrich). Proteins were eluted with 10
ml Buffer 3 (50 mM Tris–HCl pH 8.0, 0.5 mM EDTA pH
8.0, 5 mM MgCl2, 5% glycerol, 1 mM PMSF and 2 mM
2-mercaptoethanol) and fractions were separated on a 10%
SDS gel, followed by Coomassie staining and western blot-
ting to identify the PARP1 containing fractions. These frac-
tions were pooled and loaded onto a dsDNA-cellulose col-
umn (Sigma-Aldrich). Proteins were eluted with Buffer 3,
containing increasing concentrations of KCl (100 mM, 200
mM, 400 mM and 1M). The PARP1 fractions were pooled
and concentrated using anAmicon 50-kD cut-off spin filter,
for buffer exchange (storage buffer, 20% glycerol in PBS).
Protein concentration was determined using the Bradford
assay and the purified rec. PARP1 samples were aliquoted,
snap-frozen in liquid nitrogen and stored at −80◦C until
further usage.
PARP1 activity assay
PARP1 activity was performed as previously described (37),
with modifications. Reaction buffer (100 mM Tris–HCl pH
7.8, 1 mM DTT, 10 mM MgCl2 and 25 g/ml of double-
stranded DNA activator oligonucleotide, i.e. EcoRI linker)
was pre-incubated at 30◦C for 60 s. The reaction was started
by addition of 5 nM PARP1 and varying concentrations
of NAD+ (50–400 M) and was stopped by addition of
an equal volume ice-cold 20% TCA. Each sample (15% of
total) was loaded per slot in a slot-blot manifold in tech-
nical triplicates and vacuum aspirated on a Hybond-N+
nylon membrane (GE Healthcare). Purified PAR in differ-
ent concentrations (200–1500 fmol) was applied as techni-
cal standards. The slots were washed with 10% TCA and
70% ethanol before heat-crosslinking for 1 h at 90◦C. After-
wards, the membrane was blocked in M-TNT, followed by
incubation with anti-PAR antibody 10H (1:300 inM-TNT)
for 1 h. Next, themembrane was washed thrice in TNT for 5
min, followed by incubation with secondary antibody goat
anti-mouse-HRP (1:2000 in M-TNT) for 1 h. The mem-
brane was again washed thrice in TNT, followed by chemi-
luminescence detection at LAS 4000 mini (GEHealthcare).
The band intensities were evaluated densitometrically using
ImageJ software.
In silico search for PAR binding motifs
PARP1 was screened for PAR-binding motifs (PBMs)
using the PATTINPROT tool (https://npsa-prabi.ibcp.
fr/cgi-bin/npsa automat.pl?page=npsa pattinprot.html) as
described previously (41). The PBM-pattern [HKR]-
X-[AVILFWP]-[AVILFWP]-[HKR]- [HKR]-[AVILFWP]-
[AVILFWP] (42) was searched against the full-length pro-
tein sequence of PARP1 (http://www.uniprot.org/; P09874
PARP1 HUMAN), allowing for one (PBM1) or two mis-
matches (PBM2).
Far-western PAR binding assay
Rec. PARP1 was either size-separated using SDS-PAGE
and subsequent Western blotting on a PVDF membrane,
vacuum-aspirated onto a nitrocellulose membrane using a
slot-blot manifold (Roth), or, in case of the peptide stud-
ies, purchased as a membrane with covalently attached pep-
tides (PepSpot membrane with on-membrane synthesized
peptides, JPT Technologies). The PepSpot membrane was
activated in 100% methanol for 5 min according to the
manufacturer’s instructions, followed by a 5-min wash in
TNT [150 mMNaCl, 10 mMTris–HCl pH 8.0, 0.05% (v/v)
Tween 20] and a 1-h incubation in TNT. Themembrane was
then incubated over night with 0.2 Munfractionated PAR
in TNT at 4◦C. Negative controls were incubated with TNT
only, i.e. w/o PAR. The blots were subjected to three 10-
min washes with high salt buffer to remove non-specifically
bound PAR. Next, membranes were washed twice with
TNT for 10 min and blocked with 5%milk powder solution
in TNT (M-TNT) for 1 h. Subsequently, blots were incu-
bated for 1 h with anti-PAR-specific primary antibody 10H
(1:300 in M-TNT), followed by three 5-min TNT washes.
The blots were then incubated for 1 h with secondary anti-
body goat anti-mouse-HRP (Dako Cytomation, 1:2000 in
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M-TNT), followed by three 5-min washes in TNT and sub-
sequent chemiluminescence detection. Slot-blot and west-
ern blots were stripped, blocked again, and re-probed with
mouse anti-PARP1 antibody CII-10 (1:300 in M-TNT) as
loading control.
Biotinylation and size-fractionation of PAR
Biotinylation of PAR was performed as described previ-
ously (43) with some modifications. Briefly, 400 M of pu-
rified PAR were incubated for 8 h at RT in a buffer con-
sisting of 100 mM sodium acetate buffer pH 5.5, 1 mM
NaBH3CN, 4 mM EZ-Link Hydrazide-Biocytin (Thermo
Scientific). After dialysis against 100 mM sodium acetate
buffer pH 5.5 with a 2 kDa cut-off Slide-A-Lyzer Dia-
lyis cassette G2 (Thermo Scientific), PAR was ethanol-
precipitated. Concentration of PAR was determined via
UV absorbance measurements at 258 nm. The biotinylated
PAR was separated from non-biotinylated PAR by affin-
ity purification using the Pierce Monomeric Avidin Kit
(Thermo Scientific) according to the manufacturer´s in-
structions. The elution fractions were dialyzed against 100
mM sodium acetate buffer pH 5.5 followed by ethanol-
precipitation. HPLC fractionation of the biotinylated PAR
was performed as described previously (43). Briefly, the bi-
otinylated PAR was fractionated using an Agilent 1100 se-
ries HPLC with a semi-preparative DNAPac™ PA100 Bi-
oLC column (Thermo Scientific), by applying a multistep
NaCl gradient in 25 mM Tris–HCl pH 9.0, modified from
(43). The 258 nm UV absorbance signal was used to collect
PAR fractions manually, followed by ethanol-precipitation.
Electrophoretic mobility shift assays (EMSAs)
DNA-EMSAs were performed as described previously
(41). Briefly, rec. PARP1 was incubated for 20 min with 200




buffer (40 mM Tris–HCl pH 8.0, 5 mM DTT, 4 mM
MgCl2, 0.1 mg/ml BSA and 0.1% NP-40) at RT. Then,
samples were mixed with 10× loading dye (40% glycerol,
0.05% orangeG and 0.05% bromphenol blue) and loaded
on a 5% native TBE gel. The gel was blotted onto a nylon
membrane, followed by heat-crosslinking (1 h at 90◦C). The
blot was blocked for 1 h inM-TNT, washed thrice for 5 min
in TNT and then incubated for 1 h with streptavidin-HRP
(1:1000 in TNT). Afterwards, membranes were washed
thrice for 5 min in TNT followed by chemiluminescence
detection. When the effect of PAR binding on PARP’s
DNA binding ability was tested, PARP1 was pre-incubated
with unfractionated PAR (in amounts as indicated) for 20
min at RT before addition of the DNA substrate. The band
intensities were analyzed using ImageJ to calculate relative
band shifts.
PAR-EMSAs were essentially performed as described
previously (43), with modifications. Briefly, rec. PARP1 in
increasing concentration was mixed with EMSA buffer (see
above) and incubated at 25◦C for 10 min. After addition
of 500 fmol size-fractionated biotinylated PAR (30–35 mer)
the samples were again incubated at 25◦C for 20 min. The
samples weremixedwith 10× loading dye (40% glycerol and
0.05% orangeG), separated on a 5% native TBE gel by elec-
trophoresis, semi-dry blotted on nylon membrane, followed
by drying at 90◦C for 1 h. After 1-h blocking inM-TNT, the
blots were washed thrice for 5 min with TNT followed by
an 1-h incubation with streptavidin-HRP (1:1000 in TNT).
Afterwards, the blots were washed again thrice with TNT,
followed by chemiluminescence detection.
Identification of F304L variant in a patient with pediatric col-
orectal carcinoma
This patient, with non-polyposis, microsatellite stable col-
orectal cancer, diagnosed at 13 years of age, was included
in a study to identify novel CRC predisposing genes by ap-
plying exome sequencing on germline DNA. Clinical data,
tumor tissue and DNA samples were obtained. The pa-
tient and the parents provided informed consent and the
studies were approved by the Medical Ethics Committee of
the Radboud University Medical Center in Nijmegen (no.
2012/271). DNA was extracted from peripheral blood cells
and tumor tissues using standard procedures.
The exome sequencing procedures used were essentially
as reported before (44). Briefly, exome enrichment was
performed using an AB SOLiD optimized SureSelect hu-
man exome kit v1 (Agilent). Small insertions and deletions
were detected using the SOLiD Small InDel Tool. All vari-
ants were annotated using an in-house developed analysis
pipeline (44,45). For prioritization, we selected high confi-
dent non-synonymous variants that had a high probability
of being pathogenic, and were absent in dbSNPv132 and
our in-house variant database containing at time of analysis
1302 in-house analyzed exomes. The candidate mutations
were validated by Sanger sequencing in peripheral blood
DNA of the child and its parents.
Generation of PARP1-GFP expression constructs and cell
transfection
PARP1 mutants were generated by site-directed mu-
tagenesis (mutated bases are marked by bold un-
derlining). Plasmids pET15b::PARP1\V762 and
pET15b::PARP1\A762 were used as templates to gen-
erate the mutants pET15b::PARP1\V762\L304 and
pET15b::PARP1\A762\L304 using the primer pair 5′-
AATGCTCGGGTCAGCTGGTCCTCAAGAGC-3′
and 5′-GCAGTAATAGGCATCGCTCTTGAGGA
CCAGCT-3′. For rec. protein expression in Sf9 cells
the PARP1 sequences were PCR-extracted (5′- AAAC
TGGCGGCCGCATGGCGGAGTCTTCGGATAAGC-
3′ and 5′-TCGAGTGCGGCCGCTTACCACAGG
GAGGTCTTAA-3′) and sub-cloned into the pJET1.2
vector using the CloneJET PCR cloning kit (Thermo
Fisher), thereby introducing NotI restriction sites up-
and downstream of the PARP1 sequences (underlined
in primer sequence). Using these restriction sites the
PARP1 sequences were cloned into the MCS of the
baculovirus expression vector pVL1393 (BD). peGFP-
N1::PARP1\V762A, peGFP-N1::PARP1\F304L and
peGFP-N1::PARP1\F304L\V762A were generated us-
ing the pVL1393 plasmids as donors. Therefore, the
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respective pVL1393 plasmids and pEGP-N1::PARP1
were digested with BssHII and EcoRV. The result-
ing fragments were ligated in the pEGP-N1::PARP1
backbone. peGFP-N1::PARP1\E988K and peGFP-
N1::PARP1\L713F were generated by site-directed
mutagenesis using peGFP-N1::PARP1 as a template.
For peGFP-N1::PARP1\E988K the primer pair 5′-
CCTCTCTACTATATAACAAGTACATTGTCT-3′ with
5′-CATAGACAATGTACTTGTTATATAGTAGAG-3′
was used. For peGFP-N1::PARP1\L713F the primer
pair 5′-GCATACTCCATCTTCAGTGAG-3′ with 5′-
GGACCTCACTGAAGATGGAG-3′ was used. Correct
orientation of the inserts and successful mutagenesis were
verified by DNA sequencing (GATC Biotech).
For reconstitution experiments, PARP1 KO cells were
transfected with different eGFP-N1::PARP1 plasmids us-
ing Effectene (Qiagen), according to the manufacturer’s in-
structions. Briefly, DNA, EC-buffer and Enhancer were
carefully mixed and incubated for 4 min. Next Effectene
was added and the solution was again carefully mixed. Af-
ter incubation for 10 min at room temperature cell culture
medium was added and the transfection mix was pipetted
dropwise onto the cells. In order to mitigate cytotoxicity of
the transfection the medium was exchanged 12–16 h after
transfection.
Immuno-chemical detection of PARP1 and PAR by fluores-
cence microscopy
HeLaWT and HeLa PARP1KO cells were seeded on glass
cover slips in 12-well plates. PAR formation was induced
by H2O2 treatment for 5 min, 48 h after transfection. After
treatment, cells were washed once with PBS and fixed in 4%
(w/v) PFA in PBS for 20 min. All subsequent incubation
steps were performed at RT on a shaker. In order to stop
fixation, 100 mM glycine in PBS was added for 1 min fol-
lowed bywashing of the slides in PBS. For permeabilization,
the slides were incubated for 3 min in 0.4% Triton X-100 in
PBS, followed by washing with PBS.
For immunofluorescence staining, the cells were blocked
in PBS containing 20% (w/v) non-fat milk powder and
0.2% (v/v) Tween 20 (PBSMT) for 1 h. Then, samples were
either incubated with the primary antibodies mouse-anti-
PAR (10H) ormouse-anti-PARP1 (FI-23 orCII-10) at 37◦C
for 1 h. Subsequently, the slides were washed thrice for 10
min in PBS, followed by incubation with the secondary an-
tibodies goat anti-mouse IgG coupled to Alexa546 (1:400 in
PBSMT). Next, the slides were washed thrice for 10 min in
PBS, nuclei were stained with Hoechst33342 (0.1 g/ml in
PBS) for 5 min, slides were washed again in PBS thrice for
10 min, andmounted with Aqua Poly/Mount (Polysciences
Inc.). Microscopic images were acquired using a Zeiss Ax-
iovert 200M microscope. Image data for PARP1 and PAR
was analyzed using an automated KNIME workflow. Anti-
body controls, prepared without the primary antibody were
used to determine background fluorescence. Only cells with
a GFP fluorescence intensity higher than 1.5-fold of the
mean background fluorescence intensity were considered
GFP-positive and analyzed for PAR-fluorescence.
Western blot analysis
Protein lysates of PARP1-transfected HeLa PARP1 KO
cells were prepared about 40 h after transfection. To this
end, cells were trypsinized, counted and 5 × 105 cells
were centrifuged. The pellet was resuspended in 33 l
PBS containing 1× complete protease inhibitor cocktail
(Roche) and lysed by addition of 66 l SDS loading dye
(93.75 mM Tris-HCl (pH 6.8), 9 M urea, 7.5% (v/v) -
mercaptoethanol, 15% (v/v) glycerol, 3% (w/v) SDS and
0.01% (w/v) bromphenol blue). DNA was sheared through
syringes with decreasing diameters and 30l protein lysates
were loaded per lane, run on 10% SDS gels, and semi-dry
blotted onto a nitrocellulose membrane. Membranes were
blocked for 1 h in M-TNT or in TNT with 5% BSA (in
case of antibodies detecting phosphorylated proteins), fol-
lowed by 1-h incubation with primary antibodies [mouse
anti-PARP1CII-10 (1:300);mouse-anti-p53 (1:1000,Merck
Millipore); rabbit-anti-p16 (1:2000, Abcam mouse anti-
actin (1:50 000, Millipore) in M-TNT and rabbit anti-ph-
p53(Ser15) (1:1000, Cell Signaling); mouse-anti-H2A.X
(1:2000, Millipore) both in TNT with 5% BSA, rabbit anti-
phospho-RPA2 (Ser4/8) (Sigma-Aldrich)] and three 5-min
washes in TNT. Next, membranes were incubated 1 h with
the respective secondary antibodies [goat-anti rabbit-HRP
1:2000 in M-TNT (Dako); goat-anti mouse-HRP 1:2000 or
1:5000 in M-TNT (Dako)], again followed by three 5-min
washes in TNT and chemiluminescence detection.
LC–MS/MS quantitation of cellular PAR
Quantitation of cellular PAR levels by isotope dilution
mass spectrometry (LC–MS/MS) was conducted as de-
scribed previously (20), with modifications. Briefly, cells
were treated with H2O2 in concentrations as indicated for
5 min at 37◦C. Then, cells were washed briefly with ice-cold
PBS, placed on ice and lysed with 1 ml 20% TCA. The lysed
cells were harvested using a cell scraper and centrifuged for
5 min at 3000 × g and 4◦C. The supernatant was discarded,
the pellet washed twice with 500 l ice-cold 70% ethanol
and centrifuged for 5 min at 3000 × g at 4◦C. The pellet
was air-dried at 37◦C, resuspended in 255 l 0.5MKOH by
constant shaking until completely dissolved and was then
neutralized with 50 l 4.8 MMOPS buffer. For determina-
tion of DNA concentration, 30 l were removed. To each
30-l sample, 390 l MOPS:KOH (1 M:0.5 M) and 2.1 l
Hoechst 33342 (1 mg/ml) were added and fluorescence in-
tensities were measured with an extinction wavelength of
360 nm and an emission wavelength of 460 nm utilizing a
VarioskanFlash Fluorescence Reader (Thermo Scientific).
The DNA concentration of a sample was calculated us-
ing a standard curve from defined amounts of calf thymus
DNA (Sigma-Aldrich). Heavy-isotope labeled, undigested
PAR (12 pmol) was added as an internal standard. DNA
and RNA were digested for 3 h at 37◦C by incubating sam-
ples with 0.1 mg/ml DNase 1 (Roche), 0.1 mg/ml RNase
A (Sigma-Aldrich), 50 mM MgCl2 and 100 mM CaCl2.
Then, 1.25l of 40mg/ml proteinaseK (Roche) were added
and samples were incubated at 37◦C over night. Thereafter,
PARwas purified using the High Pure miRNA Isolation kit
(Roche) according to the manufacturer’s instructions. PAR
was eluted in 100 l RNase-free water and then digested
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into its subunits with 10U PDE1 (Affymetrix) and 0.5 U al-
kaline phosphatase (Sigma-Aldrich) for 3 h at 37◦C. Next,
the samples were filtered through a 10-kD Nanosep filter
(Pall) and subsequently dried in a speedvac. The samples
were then resolved in 100 l MilliQ water and subjected to
LC–MS/MS analysis.
NAD+ cycling assay
HeLaWT or HeLa PARP1KO1 cells were seeded in 6-well
plates and transfected with the different eGFP-N1::PARP1
plasmids using Effectene (Qiagen). Two days after trans-
fection, NAD+-cycling assays were performed. To this end,
PAR formation was induced by treatment with 500 M
H2O2 for 8 min. Cells were harvested using trypsin/EDTA
and kept on ice during all subsequent steps. The cell num-
bers were determined using a CASY cell counter (Roche)
and 5× 105 cells were used for analysis. Cell pellets were re-
suspended in 500 l PBS and lysed by addition of 24 l 3.5
M perchloric acid. After a 15-min incubation, samples were
centrifuged to remove cellular debris. The supernatant was
mixed with 350 l phosphate buffer (0.33 mM K2HPO4,
0.33 mMKH2PO4 pH 7.5) followed by a 15-min incubation
to allow precipitation. After centrifugation, the supernatant
was incubated on ice for 20 min followed by another round
of centrifugation. The resulting supernatant was used in the
NAD+-cycling assay. As a reference, a standard curve was
determined in each experiment. To this end, NAD+ was di-
luted to concentrations ranging for 0 M to 0.48 M. Each
sample was measured in technical triplicates and therefore
40 l of the supernatant were diluted in 160 l Diluent (0.5
MH3PO4, 0.5 MNaOH). To each well 100 l of a reaction
mix [0.48 M bicine (pH8), 4 mg/ml BSA, 0.02 M EDTA,
2.4M ethanol, 2 mMMTT, 0.96 mg alcohol dehydrogenase
and 5.7 mM phenazine ethosulfate] was added. Absorption
at 550 nm was measured after a 30-min incubation at 30◦C
using 690 nm as a reference wavelength. The intracellular
NAD+ concentration was calculated with the help of the
standard curve and normalized to the transfection efficien-
cies as determined by FACS analysis performed in parallel




) × (1 − transfection efficiency) + n (NAD+ in transfected cells)
× transfection efficiency = n (NAD+ measured)
Cell proliferation and viability analysis
For the Alamar Blue assay, a number of 4000 cells were
seeded into a 96-well plate in technical triplicates and in-
cubated for 4 h at 37◦C (defined as time point ‘0 h’). At sub-
sequent time points, Alamar Blue solution (Invitrogen) was
added and cells were incubated for an additional hour at
37◦C. The fluorescence signal was measured at 550 nm ex-
citation wavelength and 590 nm emission wavelength and
data normalized to the ‘0 h’ time point.
For annexin V /PI staining, HeLa WT and PARP1 KO
cells were seeded in 6-well plates and transfected with the
different eGFP-N1::PARP1 plasmids using Effectene (Qi-
agen). In case of treatment, camptothecin (CPT; Sigma-
Aldrich) or DMSO as solvent control were added to the
medium 24 h after transfection. Two days after treat-
ment, cells were harvested using trypsin/EDTA. The used
medium, the PBS, and the trypsin/EDTA with the fresh
mediumwere collected. The resulting cell concentrationwas
determined using a CASY cell counter (Roche). A number
of 2.5× 105 cells was pelleted and resuspended in annexin V
binding buffer (10 mMHEPES pH 7.4, 140 mMNaCl, 2.5
mM CaCl2). A volume of 195 l of the cell suspension was
mixed with 5l annexin V-FITC (for untransfected cells) or
annexin V-APC (for transfected cells) and incubated in the
dark at RT. Finally, 200 l of propidium iodide (PI) solu-
tion (10 g/ml PI in annexin V binding buffer) were added
and the cells were analyzed using a FACSCalibur (BD). For
each sample, 10 000 transfected cells were analyzed. Only
GFP-positive cells were included in the analyses.
Cell cycle analysis
HeLa WT or HeLa PARP1 KO cells were seeded in 6-well
plates and transfected with the different eGFP-N1::PARP1
plasmids using Effectene (Qiagen). Three days after trans-
fection, the cells were harvested using trypsin/EDTA, pel-
leted, and resuspended in 300 l PBS. Then, 700 l ethanol
were added for fixation, cells were incubated for 20 min fol-
lowed by centrifugation. The pellet was washed with PBS,
centrifuged again and resuspended in 30 l PBS. A volume
of 120 l of DNA extraction buffer (4 mM citric acid, 0.2
M Na2HPO4, pH 7.8) was added and the samples were in-
cubated for 20 min on a shaker at RT. After centrifugation
the samples were resuspended in PI-staining solution (PBS,
0.2 mg/ml RNAase A, 20 g/ml PI) and analyzed using
a FACSCalibur (BD). For each sample, 10 000 transfected
cells were measured. Only GFP-positive cells were included
in the analyses.
Clonogenic survival assay
Cells (1× 106 cells/ml) were incubated for 5min in the pres-
ence of H2O2 in concentrations as indicated. Subsequently,
500 cells were seeded in 6-cm plates and incubated at 37◦C,
5% CO2 and 95% humidity. After 2 weeks, medium was re-
moved and colonies were fixed and stained for 1 h using
a 10%-formaldehyde solution (Sigma-Aldrich) mixed with
0.1% crystal violet. The culture dishes were washed and
colonies consisting of at least 20 cells were counted using
a stereomicroscope (Leica).
Live imaging of PARP1 recruitment to sites of laser-induced
DNA damage
For the analysis of recruitment to DNA damage, 1 × 105
HeLa PARP1 KO cells were seeded on -slides (ibidi) 24
h before transfection with the different eGFP-N1::PARP1
constructs using Effectene (Qiagen) according to the man-
ufacturer’s instructions. Protein expression was allowed for
40 h. On the day of irradiation, the medium was changed to
phenol red-free DMEM (Invitrogen).
DNA damage was induced with a commercially available
780 nm femtosecond-pulsed fiber laser (Toptica, Munich,
Germany) coupled into a LSM700 confocal laser scanning
microscope (Zeiss) through an independent scanner system
(Rapp Optoelectronics, Hamburg, Germany). Within the
GFP-positive cell nuclei a 6 m line was irradiated for a
total irradiation time of 3.78 sec using 5 mW average power
and a repetition rate of 40 MHz. Imaging was performed
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using a Zeiss EC-Plan-Neofluar 40×/1.3 oil immersion ob-
jective lens at a wavelength of 488 nm through an open
pinhole. Acquisition of time lapses at multiple positions
was facilitated by an automated macro (LIC macro, Uni-
versity of Freiburg, Germany) and analysis was performed
with a line analysis macro for ImageJ which is available for
download on http://www.bioimaging-center.uni-konstanz.
de (BIC tool box, University of Konstanz, Germany).
Statistical analysis
Statistical testing was performed using GraphPad Prism
and tests were applied as indicated in Figure legends. *P ≤
0.05, **P ≤ 0.01, ***P ≤ 0.001.
RESULTS
Generation and characterization of HeLa PARP1 knock-out
cells
We set out to generate a genetic PARP1 KO in one of
the most widely used human cellular model systems, i.e.
HeLa cells. Recently the HeLa genome has been fully se-
quenced (46,47), enabling us to use the TALEN technology
to target exon 1 of PARP1 [MIM 173870] (Supplementary
Figure S1). We identified two independent clones, termed
PARP1KO1 and KO2, that displayed complete abrogation
of PARP1 expression, as evaluated by single-cell fluores-
cence microscopy (Figure 1A) andWestern blotting (Figure
1B). DNA sequencing of PCR amplicons of the genomic re-
gion of interest confirmed successful targeting by introduc-
ing small deletions in PARP1 exon 1 in both clones (data
not shown). To characterize how the loss of PARP1 affects
PAR metabolism, we treated HeLa WT and PARP1 KO
clones with doses of 10 M to 1 mMH2O2. As it is evident
from single-cell immuno-epifluorescence microscopy using
the anti-PAR specific antibody 10H, no PAR signal could
be observed in PARP1 KO cells even at the highest treat-
ment dose of 1mMH2O2 (Figure 1C). Next, we tested if the
loss of PARP1 affects NAD+ levels under non-stress condi-
tions as well as uponH2O2 treatment by using an enzymatic
NAD+ cycling assay based on (48). Figure 1D shows that
under non-stress conditions the loss of PARP1 did not lead
to significant changes in basal NAD+ levels. As expected,
treatment of HeLa WT cells with H2O2 led to a dramatic
drop in cellular NAD+ levels. In contrast, NAD+ levels did
not significantly change in PARP1 KO cells upon H2O2
treatment (Figure 1D). To analyze cellular PARmetabolism
in greater detail, we used a bioanalytical method based on
isotope dilution mass spectrometry, which, in contrast to
immunochemical-based technologies, is sensitive enough to
quantify basal PAR levels in unstressed cells with unequiv-
ocal chemical specificity (20). A 100-fold increase in cellular
PAR levels was observed, whenHeLaWT cells were treated
with up to 200 M H2O2. As expected this effect could be
largely inhibited by treating cells with the pharmacologi-
cal PARP inhibitor ABT888 (10 M) (Figure 1E). Resid-
ual PARP activity in the presence of 10 M ABT888 has
been observed before (20) and can be attributed to themuch
higher sensitivity of the LC–MS/MS method as compared
to the immunofluorescence analysis, which is not able to de-
tect this residual PARP activity (20). HeLaPARP1KO cells
Figure 1. TALEN-mediated gene targeting of PARP1 in HeLa cells. (A)
Single-cell immuno-epifluorescence analysis of PARP1 expression inHeLa
WT and in two independently generated PARP1 knock-out (KO) clones
(KO1 and KO2). (B) Western blot analysis of PARP1 expression in HeLa
WT and PARP1KO clones. PCNA served as a loading control. (C) Single
cell immuno-epifluorescence analysis of PAR formation in HeLa WT and
PARP1KO clones. WT cells showed a dose-dependent increase in cellular
PAR levels upon H2O2 treatment (for 5 min), while PAR levels in PARP1
KO cells remained close to background signal intensities. Representative
epifluorescent microscopic images (left panel), quantitation of image data
(right panel). Means ± SEM, at least 70 cells per data point were ana-
lyzed. Statistical analysis was performed via two-way ANOVA testing and
Sidak’s post-test. (D) Intracellular NAD+ levels in WT and PARP1 KO
cells ± H2O2 treatment for 7 min as measured by an enzymatic NAD+
cycling assay. Means ± SEM of n = 3 independent experiments. Statis-
tical analysis was performed using two-way ANOVA testing and Sidak’s
post-test. (E) Quantitation of basal and H2O2-induced PAR levels in WT
andPARP1KOcells via isotope dilutionmass spectrometry (LC–MS/MS)
using a previously published method (20). To induce PAR-formation, cells
were treatedwithH2O2 as indicated. If indicated, cells were pretreatedwith
10 MABT888 for 45 min. Insert: Basal PAR levels in untreated WT and
PARP1 KO cells. Means ± SEM of n = 3 independent experiments. Sta-
tistical analysis was performed using one-way ANOVA testing and Sidak’s
post-test within one group of cells (i.e. WT, KO1, KO2). (F) LC–MS/MS
analysis of PAR levels± camptothecin (CPT) treatment for 30min.Means
of n = 2 independent experiments. R-Ado indicates ribosyl-adenosine.
showed only a 5–7-fold increase in PAR levels, which could
be completely inhibited byABT888 treatment. These results
demonstrate that upon induction of severe genotoxic stress,
PARP1 contributes to >90% of cellular PAR formation in
HeLa cells. The residual PAR forming ability can be prob-
ably attributed to other DNA damage dependent PARPs,
such as PARP2 and PARP3 (49). Importantly, while stress-
induced PAR formationwas almost completely abolished in
PARP1KO cells, basal PAR levels remained constant, indi-
cating that under physiological, non-stress conditions other
PARPs can compensate for the loss in PARP1 (insert in Fig-
ure 1E). Recently, it has been shown that PARP1 plays a
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crucial role in the response of cells to camptothecin (CPT)
treatment (50,51). Using our highly sensitive LC–MS/MS
technique, we analyzed if CPT treatment directly stimulates
PARP activity in HeLa cells. As shown in Figure 1F, CPT
treatment for 30 min led to a significant induction of PARP
activity, yet this induction was far moremoderate than after
H2O2 treatment. Thus, a 1-Mtreatment led to∼2-fold and
a 100-MCPT treatment to 4-fold higher PAR levels com-
pared to basal PAR levels in untreated cells. Importantly,
this increase in PAR can be completely attributed to PARP1
activity, since no increase in PAR levels was observed in
PARP1 KO cells.
After having analyzed PAR metabolism in HeLa PARP1
KO clones, we characterized cellular and functional con-
sequences of the genetic deletion of PARP1. When cultur-
ing HeLa PARP1 KO cells, it became apparent that these
cells grew considerably slower compared to their WT coun-
terparts. In agreement with this observation, proliferation
analysis revealed that both PARP1 KO clones showed sig-
nificantly slower proliferation rates compared to WT, while
the overall cell cycle distribution appeared to be unaffected
(Figure 2A and B). A plethora of reports from Parp1 KO
mice and human cell culture studies usingRNA interference
and pharmacological inhibition of PARP activity showed
that loss of PARP1 leads to a sensitization of cells towards
genotoxic stimuli (31,32,52). To test if the same holds true in
genetically-targeted HeLa PARP1 KO cells, we performed
a clonogenic survival analysis of HeLa WT and PARP1
KO cells upon H2O2 treatment. Consistent with data from
other mammalian systems, loss of PARP1 led to a signif-
icant sensitization of HeLa cells towards low-dose H2O2
treatment (Figure 2C). Next, we analyzed how PARP1 defi-
ciency affects the response of HeLa cells to CPT treatment
by performing cell viability and cell cycle analyses. Figure
2D demonstrates that HeLa PARP1 KO clones were sig-
nificantly sensitized to CPT treatment, resulting in lower
cell viability two days after CPT treatment, which could be
attributed to both increased apoptosis as well as necrosis
rates. Interestingly, in terms of necrosis, the two indepen-
dently generated PARP1 KO clones showed significant dif-
ferences, with clone KO2 showing higher necrosis induction
than cloneKO1. Such slight differences in the phenotypes of
the two clones are not unexpected, since selection processes
may occur during culturing of the clones, before initial bio-
chemical analysis by immunofluorescence microscopy and
Western blotting. To analyze if also nanomolar doses of
CPT, which are assumed to induce primarily replicative
stress without directly inducing DNA strand breaks, lead to
a sensitization ofPARP1KO cells, we performed a cell cycle
analysis two days after CPT treatment (Figure 2E). These
experiments revealed that CPT treatment caused a strong
G2 arrest that was significantly increased in both PARP1
KO clones. Since both PARP1 KO clones showed similar
properties, we focused on the usage of clone PARP1 KO1
for further analyses.
In summary, we have generated a complete genetic
knock-out of PARP1 in HeLa cells in two independent
clones. Furthermore, we provide a detailed characteriza-
tion of these cells with regards to their PAR and NAD+
metabolism, their growth characteristics, and their cellu-
Figure 2. Functional consequences of PARP1 deletion in HeLa cells. (A)
Cell proliferation of HeLa WT and PARP1 KO cells as analyzed by Ala-
mar Blue assay for 3 days. Means ± SEM of n = 3 independent experi-
ments. Statistical analysis was performed using two-way ANOVA testing
and Sidak’s post-test. (B) Cell cycle analysis of untreated WT and PARP1
KO cells via PI staining and subsequent flow cytometric analysis. Means±
SEM of three independent experiments. (C) Clonogenic survival analysis.
HeLa WT and PARP1 KO cells were treated with H2O2 as indicated for
5 min and then plated and cultivated for 2 weeks prior to colony count-
ing. Means ± SEM of n = 3 independent experiments. Statistical analy-
sis using two-way ANOVA testing and Sidak’s post-test. (D) Cytotoxicity
analysis via annexin V/PI staining and subsequent flow cytometric anal-
ysis of HeLa WT and PARP1 KO cells treated ± CPT in concentrations
as indicated for 2 days. Viable cells refer to annexin V/PI-double negative
cells (top); early apoptotic cells to annexin V-positive (middle), PI-negative
cells; and necrotic and late-apoptotic cells to annexin V/PI-double positive
cells (bottom). Ratios compared to total cell numbers. Means ± SEM of
n ≥ 4 independent experiments. Statistical analysis was performed using
two-way ANOVA testing and Sidak’s post-test. (E) Cell cycle analysis via
PI staining and flow cytometric analysis 2 days after treatment of cells ±
CPT in concentrations as indicated. Means ± SEM of n ≥ 4 independent
experiments except for data of PARP1KO2 cells; n= 1. Statistical analysis
was performed using two-way ANOVA testing and Sidak’s post-test.
lar responses after application of the genotoxins H2O2 and
CPT.
Reconstitution of HeLa PARP1 knock-out cells with PARP1
variants
By reconstitutingHeLaPARP1KO cells with select PARP1
variants, we examined the cellular biochemistry of those.
First, to exemplify the potential of this system for its usage
in PARylation research, we analyzed two artificial PARP1
mutants that are of high interest to understand the cellular
biochemistry of PARylation, i.e. a hypomorphic (E988K)
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Figure 3. Overview of PARP1 variants included in this study. (A) PARP1
structure and localization of amino acid exchanges of PARP1 variants
as used in this study. The 3D structure is in complex with a double-
stranded DNA molecule [PDB code 4DQY (3)], without ZnF2 and WGR
domains. (B) Biochemical parameters derived from rec. enzymes of the
different PARP1 variants used in this study. Values were determined in
the present study (cf. Figure 9) or taken from the literature as indicated.
PAR indicates poly(ADP-ribose); MAR, mono(ADP-ribose); and OAR,
oligo(ADP-ribose). (C) Western blot analysis of PARP1 protein levels in
HeLa PARP1KO cells reconstituted with different PARP1-eGFP variants
2 days after transfection. Left: representative Western blot out of 4. Right:
densitometric analysis of western blot signal intensities after normaliza-
tion to transfection efficiencies. Means ± SEM of n = 4 independent ex-
periments. Statistical analysis was performed using 1-sample t-test com-
paring the expression of the different PARP1-variants after transfection
to endogenous PARP1\WT-levels in HeLa cells.
and a hypermorphic (L713F) PARP1 mutant (Figure 3A).
Using a second set of PARP1 variants, we then analyzed
biochemical and cellular properties of naturally occurring
PARP1 variants, i.e. a PARP1 polymorphism that has been
associated with increased risk for certain cancers (V762A)
and a newly identified inherited PARP1 mutant in a patient
with pediatric colorectal carcinoma (F304L) (Figure 3A).
Figure 3B gives an overview of the biochemical parameters
of the different variants as reported in the literature and the
current study (see below). We generated eukaryotic expres-
sion constructs of the PARP1 variants using site-directed
mutagenesis. To detect PARP1 expression in transfected
HeLa cells and to monitor recruitment to sites of DNA
damage, all variants were C-terminally tagged with eGFP.
A transient-transfection approach was chosen to avoid po-
tential counter-selection effects during cell culturing. As it is
evident from Western blot (Figure 3C) and FACS analyses
(Supplementary Figure S2), reconstitution of HeLaPARP1
KO cells with these constructs led to a strong expression of
the PARP1 variants, which was ∼4-5-fold higher than en-
dogenous PARP1 expression in HeLa WT cells, with the
exception of the PARP1\L713F variant, which showed per-
cell expression levels comparable to WT cells. It is obvious
that PARP1 protein levels may influence many cellular pro-
cesses, although only weak correlations between PARP1 ex-
pression levels and PAR formation under non-stressed and
upon genotoxic stress have been observed, indicating that
PARP1 expression alone is not the limiting factor for PAR
production (data not shown). In subsequent experiment,
we included both HeLa WT cells as well as PARP1\WT-
reconstituted cells as controls, which allows the assessment
of any potential effects of PARP1 protein levels on func-
tional outcomes.
Reconstitution of HeLa PARP1 knock-out cells with wild-
type and artificial PARP1 variants
In the first set of PARP1 mutants, we focused on a hypo-
morphic PARP1 mutant, with an aa exchange from glu-
tamate to lysine at position 988 (E988K), and on a hy-
permorphic PARP1 mutant, with an aa exchange from
leucine to phenylalanine at position 713 (L713F). Pre-
viously, PARP1\E988K was shown to exhibit mono- or
oligo(ADP-ribosyl)ation activity in biochemical studies us-
ing recombinant enzymes (37,53,54) and its cellular behav-
ior has been characterized by reconstituting mouse em-
bryonic fibroblasts derived from Parp1 knock-out mice
(51,55). The PARP1\L713F mutant was originally iden-
tified as a gain-of-function mutant in a random mutage-
nesis screen and has been characterized on a biochemi-
cal level (3,56,57). Thus, this mutant mimics the effect of
DNA-binding-induced distortions in the catalytic domain,
thereby increasing PARP1 DNA-independent activity in-
vitro up to 20-fold and elevating the catalytic efficiency of
PARylation, while not affecting its affinity for NAD+ (3)
(Figure 3B). To the best of our knowledge, so far this vari-
ant has not been characterized in a cellular environment.
Cellular PAR and NAD+ metabolism of artificial PARP1
mutants. To provide a basis for the analysis of cellu-
lar consequences of reconstituted HeLa PARP1 KO cells,
we conducted a detailed characterization of the cellular
biochemistry of the different PARP1 variants with re-
gards to PARylation and NAD+ metabolism as well as
PARP1 localization dynamics at sites of DNA damage.
Using triple-color immuno-epifluorescencemicroscopy and
image evaluation by an automated KNIME workflow,
we examined the PARylation response upon treatment of
PARP1-reconstituted cells with increasing doses of H2O2.
As expected, PARP1-reconstituted cells showed a dose-
dependent PAR formation (Figure 4A and B). The re-
sponse was similar to the dose-response that had been ob-
served in HeLa WT cells (Figure 1), however, in contrast
to HeLa WT cells, saturation of PAR signals was reached
already at a dose of 500 M, presumably because of mod-
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Figure 4. Cellular biochemistry of artificial PARP1mutants.HeLaPARP1
KO cells were transfected with eGFP-coupled constructs of PARP1,
PARP1\L713F and PARP1\E988K. Analyses were performed 2 days
after transfection. (A) Representative images from single cell immuno-
epifluorescence analysis of PARP1-eGFP and PAR after treatment of
PARP1-reconstituted cells ± H2O2 as indicated for 5 min. Scale bars in-
dicate 30 m. (B) Densitometric analysis of imaging data as shown in
(A). More than 100 cells were analyzed per experiment and condition in
a semi-automated manner using a KNIME workflow. Means ± SEM of n
= 4 independent experiments. Statistical analysis using matched two-way
ANOVA testing and Sidak’s post-test. (C) Time-course analysis of PAR
levels in PARP1-reconstituted cells after treatment of cells with 250 M
H2O2. Means ± SEM of n = 4 independent experiments, >100 cells were
analyzed per experiment and condition. Statistical analysis was performed
using matched two-way ANOVA testing and Sidak’s post-test. (D) LC–
MS/MSanalyses of PAR levels inPARP1KO1 cells and cells reconstituted
with PARP1\WT and PARP1\L713F. Two days after transfection, cells
were treated as indicated for 7 min. Levels were normalized to transfec-
tion efficiencies. Means ± SEM of n = 3 independent experiments. Statis-
tical analysis was performed by one-wayANOVA testing and Tukey’s post-
test. (E) Western blot analysis of HeLa cell extracts of KO1 and PARP1-
reconstituted cells, as indicated. 2 days after transfection, cells were treated
with 500 M H2O2 for 7 min. PARylated proteins were detected via the
10H antibody. Red arrows indicate the expected molecular weight of auto-
PARylated PARP1. (F) NAD+ levels in PARP1-reconstituted cells upon
treatment ± H2O2 for 7 min as measured by an enzymatic NAD+ cy-
cling assay. Means ± SEM of n = 3 independent experiments, except for
ABT888-treated samples, n = 2. Statistical analysis was performed using
two-way ANOVA testing and Sidak’s post-test.
erate PARP1 overexpression in reconstituted cells (Supple-
mentary Figure S3). PARP1\E988K-reconstituted cells did
not reveal any significant increase in PAR-derived fluores-
cent intensities (Figure 4A and B), which is in accordance
to its described mono-/oligo-(ADP-ribosyl)ation activity
(37,53,54). These results are in agreement with time-course
analysis of PAR formation in PARP1-reconstituted cells
upon H2O2 treatment, which revealed a transient PARy-
lation response with peak levels of PAR formation at ∼5
min after treatment. Thirty minutes after H2O2 treatment,
PAR levels returned to basal levels, due to the activity of
PAR-degrading enzymes such as PARG (Figure 4C and
Supplementary Figure S4). Furthermore, time-course anal-
ysis confirmed the inability of the PARP1\E988K variant
to produce PAR (Supplementary Figure S4). On the other
hand, cells reconstituted with PARP1\L713F produced
PAR even in the absence of exogenous DNA damage, in-
dicating that it is constitutively active not only in a cell-free
system (3), but also in a cellular environment (Figure 4A
and B). Interestingly, treating PARP1\L713F-reconstituted
cells with H2O2 for 5 min did not lead to a further in-
crease in PAR signal in IF analysis. Time-course analysis of
H2O2-treated PARP1\L713F-reconstituted cells, however,
revealed that 30 min after the genotoxic stimulus, PAR lev-
els declined to basal levels as observed in untreated HeLa
WT cells (Figure 4C), indicating that PARP1\L713 can still
be stimulated by DNA damage presumably leading to a de-
pletion of NAD+. Validation of these results using isotope
dilutionmass spectrometry, confirmed that PARP1\L713 is
constitutively active in cells, leading to 2.5-fold higher PAR
levels in unstressed cells (Figure 4D). LC–MS/MS analy-
sis also revealed that PAR levels in PARP1\WT-transfected
cells increased by ∼43-fold after H2O2 treatment, while
PAR levels of PARP1\L713F-transfected cells increased by
∼14-fold compared to unstimulated PARP1\WT- and ∼6-
fold compared to unstimulated PARP1\L713F-transfected
cells (Figure 4D). Comparison of LC–MS/MS and im-
munochemical analyses also demonstrate that immunofluo-
rescence analysis can only give a semi-quantitative estimate
of intracellular PAR levels, due to lack of sensitivity and the
limited dynamic range for quantitation (20).
To test if constitutively active PARP1\L713F leads to
PARP1 automodification, we performed western-blotting-
based PAR detection using the 10H antibody. Figure 4E
demonstrates that H2O2 treatment leads to PARP1 auto-
modification in HeLa WT cells as well as in PARP1\WT-
reconstituted HeLa PARP1 KO1 cells (indicated by
red arrows). As expected, H2O2 treatment of E988K-
reconstituted cells did not result in a significant in-
crease in PAR signal intensity. In agreement with IF and
LC–MS/MS analyses, H2O2 treatment triggered PARy-
lation and PARP1 automodification in PARP1\L713F-
reconstituted cells. However, no PARP1 automodification
could be observed in untreated cells, suggesting that con-
stitutive activity of PARP1\L713F mainly produces PAR
attached to other proteins than PARP1 or not covalently
bound to proteins at all.
To obtain further insight into the activities of PARP1
variants in reconstituted cells, we analyzed NAD+ levels
in untreated as well as in H2O2- and PARP inhibitor-
treated cells. Transfection efficiencies of individual sam-
ples were determined in parallel via flow cytometry and
have been taken into account in Figure 4F. These experi-
ments confirmed that, as expected, cells reconstituted with
PARP1\WT for two days responded similar as HeLa WT
cells by showing a drastic drop in NAD+ levels upon H2O2
treatment, which could be completely inhibited by ABT888
(Figure 4F). Unexpectedly, cells that had been reconsti-
tuted with PARP1\E988K, displayed a significant increase
in total NAD+ amounts per cell compared to PARP1\WT-
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reconstituted cells. Furthermore, H2O2 treatment led to a
moderate, but statistically significant, drop in NAD+ levels,
which is consistent with the fact that the PARP1\E988K
mutant acts as a mono- or oligo-(ADP-ribose) transferase,
which is incapable to form PAR chains that can be recog-
nized by the 10H antibody. Strikingly, the increase inNAD+
levels in PARP1\E988K-reconstituted cells could be com-
pletely inhibited by PARP inhibitor treatment (Figure 4F),
suggesting that the mono- or oligo(ADP-ribosyl)ation ac-
tivity of PARP1\E988K is responsible for the effect ob-
served. Consistent with our PARylation analysis, NAD+
levels in PARP1\L713F-reconstituted cells were reduced by
>40% under basal conditions and showed a total exhaus-
tion in H2O2-treated cells, which could be completely abol-
ished by PARP inhibitor treatment.
In summary, these results demonstrate that single aa
exchanges within PARP1 can cause dramatic effects on
PARP1’s enzymatic activity and NAD+ metabolism in a
cellular environment. This holds true for both (i) a hypo-
morphic exchange, such as E988K, thereby generating a
mono- or oligo(ADP-ribosyl) transferase, or (ii) a hyper-
morphic exchange, such as L713F, thereby generating a con-
stitutively active PARP1 variant, whose enzymatic activity
is partially uncoupled from itsDNAbinding ability andme-
diates the synthesis of mainly free PAR in cells under non-
stressed conditions.
Recruitment dynamics of artificial PARP1 mutants to DNA
damage. Since enzymatic PARP1 activation is in many
cases directly related to itsDNAbinding status, we analyzed
the spatio-temporal dynamics of recruitment of PARP1-
eGFP to DNA damage sites induced by multi-photon irra-
diation in the infrared spectrum (58,59). For PARP1\WT,
we observed a fast and strong recruitment to sites of DNA
damage reaching its maximum level 1 min after damage
induction and decreasing progressively thereafter (Figure
5A and B). This is consistent with what has been ob-
served previously in other cellular systems (55,60). For
PARP1\E988K the maximum level of recruitment was re-
duce by 50% as compared to WT. Interestingly, this level
remained unchanged over a period of 6 min after laser-
induced damage. Thus, in contrast to PARP1\WT, there
was no decrease of PARP1/E988K at the damage site
during the time of experimental observation. These re-
sults are largely consistent with the binding dynamics of
PARP1\E988K at UV-irradiated sites reported in a mouse
system (55). Recruitment experiments using the constitu-
tively active mutant PARP1\L713F revealed a similar over-
all behavior of this mutant as compared to PARP1\WT,
with a moderate, but significant reduction in the maximum
level of recruited protein. Altogether, these data demon-
strate that the dynamics of PARP1 recruitment at micro-
irradiated sites is strongly affected by the protein’s activity.
Non-covalent PARP1–PAR interaction. In many in-
stances, recruitment of DNA repair factors is mediated by
non-covalent PAR-protein interactions (19). The recruit-
ment kinetics of PARP1\E998K as observed in the current
study and by (55) suggest that non-covalent binding to
locally formed PAR may affect PARP1 binding to sites
of DNA damage. Non-covalent PARP1–PAR interaction
may lead to conformational changes within the secondary
and tertiary structure of PARP1, thereby regulating its
binding to DNA. Previously studies reported non-covalent
PARP1–PAR interaction (18,61,62). Thus, using a peptide
array-approach, Chapman et al. reported a multitude of
potential PAR binding sites within the PARP1 protein
sequence (18). Moreover, Huambachano et al. reported
PAR binding to the ZnF2 and a C-terminal region of
PARP1, i.e. dsDNA binding domain (62), but in the latter
case the binding site has never been specified. To the best
of our knowledge, a comprehensive characterization of
PAR binding to full-length PARP1 has not been reported
so far. Therefore, we tested if PARP1 and PAR interact
non-covalently, which could lead to an accumulation of
PARP1 molecules at sites of DNA damage. To this end, we
used three different biochemical approaches to characterize
the non-covalent interaction of PAR with full length rec.
PARP1. (i) We performed Western blotting of rec. PARP1,
incubated membranes in the presence or absence of in-
vitro synthesized PAR, and detected bound PAR under
high-stringency conditions. Figure 6A demonstrates that
PARP1 interacts with PAR non-covalently. (ii) This result
was further confirmed by immuno-slot blotting (Figure
6B). Both methods analyze binding of PAR to rec. PARP1
immobilized on a membrane. (iii) To analyze PARP1–PAR
interaction in solution, we performed a modified EMSA
using biotin-end-labelled PAR of defined chain length
as a bait. We observed the formation of three defined
macromolecular complexes further confirming that PARP1
interacts with PAR in a non-covalent manner (Figure
6C). In general, non-covalent PAR-protein binding can be
mediated by several different PAR binding modules (19).
The most abundant one within the human proteome
is the PAR binding motif (PBM), which comprises
a weakly conserved consensus sequence containing a
basic/hydrophobic core helix. Using a previously published
target sequence (41,42), we searched for putative PBMs
within the PARP1 aa sequence and identified two potential
binding sites within ZnF2 and ZnF3, respectively (Figure
6D). No PBM has been identified in the C-terminal region
of PARP1. [N.B. As stated above, it is important to note
that the molecular basis of the PARP1–PAR interaction is
probably highly complex and other binding sites as shown
by (18,62) presumably contribute to non-covalent PARP1–
PAR interaction.] To test if these aa sequences mediate PAR
binding in vitro, we used membrane-immobilized peptides
(PepSpot approach) in a PAR overlay assay. PBM1 showed
a strong and PBM2 aweak PARbinding (Figure 6E), which
could be completely abolished by exchanging critical lysines
with alanines.
Next, we were interested in potential functional conse-
quences of the PARP1–PAR interaction. Based on the pres-
ence of a PBM within ZnF2, we speculated that the non-
covalent PARP1–PAR interaction could directly affect the
ability of PARP1 to bind to DNA. To test this hypothesis,
we performed EMSAs of PARP1-DNA complexes formed
in the presence or absence of PAR. These results show that
PARP1 binds to this DNA substrate in a dose-dependent
manner and, importantly, this binding could be already in-
hibited by the presence of PAR in a molar ratio as low as
1:10 (PAR:PARP1) (Figure 6F).
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Figure 5. Recruitment and dissociation kinetics of PARP1-eGFP at sites of laser-induced DNA damage. (A) Representative imaging data. Scale bars
indicate 10 m. (B) Densitometric quantitation of signal intensities from imaging data as shown in (A). Means ± SEM of n = 3 independent experiments,
>29 cells were analyzed per experiment and condition. Statistical analysis was performed using two-way ANOVA testing and Sidak’s post-test.
In summary, these results demonstrate that PARP1 ac-
tivity is necessary for the efficient recruitment to as well
as release from sites of laser-induced DNA damage. Fur-
thermore, direct non-covalent PARP1–PAR interaction can
contribute to these effects by (i) efficiently attracting PARP1
molecules to sites of active PARylation and (ii) subsequently
regulating the release of highly modified PARP1 molecules
from DNA.
Cellular consequences of PARP1 reconstitution. Having
analyzed the cellular biochemistry of the PARP1\E988K
and PARP1\L713F mutants in the absence of any poten-
tially interfering endogenous PARP1\WT, we examined
potential cellular consequences of the altered PARylation
metabolism in PARP1-reconstituted cells. PARP1\E988K-
reconstituted cells showed considerable alterations in cellu-
lar morphology. Thus, we observed that PARP1\E988K ex-
pression induced significant changes in flow cytometric dot-
blots. Forward (FSC) and side scatter (SSC) intensities were
significantly increased (Supplementary Figure S5A). Fur-
thermore, when we quantified the areas of nuclei from epi-
fluorescence microscopic images of reconstituted cells, we
observed that nuclei of PARP1\E988K-reconstituted cells
were ∼50% enlarged compared to PARP1\WT, PARP1
KO and other PARP1-reconstituted cells (Supplementary
Figure S5B). In addition, 3D deconvolution microscopy
of Hoechst33342-labeling revealed signs of altered nuclear
architecture of PARP1\E988K-expressing cells as com-
pared to PARP1\WT. Thus, nucleoli of PARP1\E988K-
reconstituted cells appeared enlarged and surrounded by
compacted perinucleolar heterochromatin (Supplementary
Figure S5C).
While we could not observe any significant changes
for the chromatin markers H3K27me3 and H3K4me3 in
PARP1-reconstituted cells (data not shown), another cause
for differences in nuclear sizes may be alterations in cell
cycle regulation (63). To test if PARP1\E988K reconsti-
tution led to alterations in cell cycle distribution, we ana-
lyzed the cell cycle status of reconstituted cells via PI stain-
ing and flow cytometric analysis. While expression of the
PARP1\L713F mutant only slightly influenced the HeLa
cell cycle without application of additional stress, expres-
sion of the PARP1\E988K mutant induced a strong G2 ar-
rest three days after transfection (Figure 7A). Importantly,
PARP inhibitor treatment of PARP1-reconstituted cells did
not affect the cell cycle status at all, but, remarkably, res-
cued the cell cycle defect of PARP1\E988K-expressing cells
completely. These results are consistent with our analy-
sis of the NAD+ status in PARP1\E988K-reconstituted
cells and indicate an active role of mono- or oligo(ADP-
ribosyl)ation in inducing the observed effects. Typically, a
G2 arrest in cell cycle progression can be caused by ac-
cumulating DNA damage. To test if PARP1\E988K ex-
pression leads to a DNA damage response, we analyzed
several key factors of DNA damage signaling in PARP1-
reconstituted cells, such as phosphorylated p53 at ser-
ine 15 (ph-p53), H2A.X, and p16 (Figure 7B). West-
ern blot analysis revealed that PARP1\L713F-expressing
cells showed slightly enhanced H2A.X levels, whereas
PARP1\E988K-expressing cells exhibited a robust increase
in H2A.X and ph-p53 staining two days after transfec-
tion, while p16 expression was not affected in cells ex-
pressing PARP1 mutants. As expected, PARP inhibition
by ABT888 also induced H2A.X levels in HeLa WT
and PARP1\WT-reconstituted cells (Figure 7C). How-
ever, unexpectedly, PARP inhibition in PARP1\E988K-
reconstituted cells led to reduced H2A.X levels, indi-
cating that DNA damage induction in PARP1\E988K-
reconstituted cells is mediated by residual mono- or oligo-
(ADP-ribosyl)ation activity of the PARP1\E988K mutant
and not due to a potential PARP1 trapping effect. The
increase in nuclei size, G2 arrest and increased levels of
H2A.X observed for PARP1\E988K-reconstituted cells
is reminiscent of replicative stress, as previously observed
in hydroxyurea-treated cells (64). Of note, PARP1\E988K-
reconstitued cells showed increased levels of the replica-
tive stress marker phRPA2 (Ser 4/8), which can be miti-
gated by PARP inhibitor treatment (Figure 7D), suggesting
that the observed phenotype is directly induced by resid-
ual PARP1\E988K activity rather than a trapping effect of
PARP1\E988K at sites of DNA damage. In support of the
toxic effect of PARP1\L713F expression is the finding that
PARP inhibitor treatment led to a considerable increase in
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Figure 6. Non-covalent PARP1–PAR interaction. (A) Analysis of
PARP1–PAR interaction by PAR overlay assay using increasing amounts
of recombinant PARP1 as indicated. After protein transfer, membranes
were incubated with (left panel) or without (right panel) purified PAR
(0.2 M). PAR binding was detected using the 10H antibody after high-
stringency washing to remove non-specifically bound PAR. (B) Immuno
slot-blot PAR binding assay using increasing amounts of recombinant
PARP1. Membranes were incubated with PAR (0.2 M) and bound PAR
was detected using the 10H antibody after high-stringency washing. (C)
Analysis of PARP1–PAR interaction in solution using a modified PAR-
EMSA. End-biotinylated PAR of defined chain length (30–35 mer, 0.5
pmolADP-ribose) was incubatedwith recombinant PARP1. PARP1–PAR
binding was assessed by native TBE gel electrophoreses and Western blot-
ting. Three distinct complexes (1–3) were formed in a PARP1-dependent
manner. (D) Upper panel. In silico search for putative PAR-binding sites
within the PARP1 sequence using the search sequence displayed at the top
of the panel. Two potential PAR binding motives (PBMs), i.e. PBM1 (1
mismatch) and PBM2 (two mismatches), were identified in Zn2 and Zn3,
respectively. Lower panels. Localization of PBM1 and PBM2 within Zn2
andZn3, respectively. Structures based onPDB codes 4AV1 and 4DQY (3).
(E) PAR binding ability of peptides comprising aa sequences of PBM1/2
and peptides comprising aa exchanges potentially responsible of PBM-
PAR interactions using a PepSpot analysis. ‘AA pos.’ indicates aa positions
within full-length PARP1 sequence (85). A peptide sequence derived from
a PBM in XRCC1 served as a positive control. (F) DNA-PARP1 EMSA
using a known biotinylated double-stranded DNA oligonucleotide (200
fmol). Left. DNA-PARP1 interaction in the absence of PAR.Middle. Rec.
PARP1 (100 nM) was incubated with increasing concentrations of PAR as
indicated. Right. Densitometric evaluation of EMSAs. Means ± SEM of
n = 3 independent experiments. Statistical analysis was performed using
1-way ANOVA testing and Sidak’s post-test.
PARP1\L713F expression in PARP1 KO cells (Figure 7C
and D).
Since PARP1\E988K-expressing cells entered a G2 ar-
rest, we assumed that expression of this variant could in-
duce cell death in HeLa cells. We analyzed cell viability via
annexin V/PI staining three days after transfection. Cells
overexpressing PARP1/WT showed comparable viability
as HeLa WT cells (compare Figures 2 and 8). Consistent
with a G2 arrest, PARP1\E988K-expressing cells showed
a higher rate of early as well as late apoptotic/necrotic
cells compared to PARP1\WT-reconstituted cells, at a
Figure 7. PARP1\E988K affects cell cycle regulation and induces DNA
damage signaling. (A) Cell cycle analysis by PI staining and subsequent
flow cytometric analysis 3 days after transfection of HeLa PARP1 KO
cells reconstituted with PARP1\WT, PARP1\E988K and PARP1\L713F.
PARP1\E988K induces a G2 arrest, which can be rescued by treating cells
with 10 M ABT888. Means ± SEM of n = 6 independent experiments,
except of ABT888-treated samples, n = 2. Statistical analysis was per-
formed using two-way ANOVA testing and Sidak’s post-test. (B) Analysis
of DNA damage response markers, i.e. phospho-S15-p53, H2A.X and
p16 in WT, PARP1KO and PARP1-reconstituted cells as indicated 2 days
after transfection. Cells reconstituted with PARP1\E988K displayed in-
creased phospho-S15-p53 and H2A.X levels and cells reconstituted with
PARP1\L713F showed slightly elevated H2A.X levels. Immunochemi-
cal detection of PARP1, p53 and actin served as controls. Shown is a rep-
resentative experiment out of three. (C) Western blot analysis of ph-p53
and H2A.X levels in PARP1-reconstituted cells (±10-MABT888 treat-
ment). (D) Western blot analysis of the replicative stress marker phospho-
RPA2 (Ser4/8) in PARP1-reconstituted cells (±10-M ABT888 treat-
ment). Immunochemical detection of PARP1 and actin served as controls.
similar level compared to HeLa PARP1 KO cells trans-
fected with a plasmid carrying GFP only (i.e. labeled
with GFP-cont in Figure 8A). More strikingly, however,
expression of PARP1\L713F in HeLa PARP1 KO cells
revealed to be highly cytotoxic reducing viability from
80% for PARP1\WT-reconstituted cells to ∼40–50% for
PARP1\L713F-reconstituted cells (Figure 8A). Most of
this effect could be attributed to annexin V-positive, but PI-
negative cells indicating that high basal PAR levels in these
cells could drive cells into apoptosis without any obvious
induction of cell cycle arrest in viable cells (at least under
the conditions tested). Interestingly, pretreatment with the
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Figure 8. PARP1 mutants influence cell viability and cell cycle progres-
sion upon CPT treatment. (A and B) Analysis of viable, apoptotic and
necrotic cells 3 days after transfection of HeLa PARP1 KO cells recon-
stituted with PARP1, PARP1\E988K, and PARP1\L713F by annexinV /
PI staining and subsequent flow cytometric analysis. GFP cont indicates
cells transfected with a plasmid carrying only GFP. Cells were treated (A)
with CPT in concentrations as indicated 24 h after transfection or (B) with
10 M ABT888 directly after transfection. Viable cells refer to annexin
V/PI-double negative cells; (early) apoptotic cells to annexin V-positive,
PI-negative cells; and necrotic and late-apoptotic cells to annexin V/PI-
double positive cells (ratios compared to total cell numbers). Means ±
SEM of n≥ 3 independent experiments. Statistical analysis was performed
using two-way ANOVA testing and Sidak’s post-test. (C) Cell cycle analy-
sis of PARP1-reconstituted cells as indicated 3 days after transfection and
2 days after CPT treatment via PI staining and subsequent flow cytomet-
ric analysis. Means ± SEM of n = 3 independent experiments. Statistical
analysis was performed using two-way ANOVA testing and Sidak’s post-
test.
pharmacological PARP inhibitor ABT888 was able to mit-
igate the induction of early apoptosis, indicating, that not
the PARP1\L713F protein itself, but the constitutive activ-
ity of this variant is responsible for the increased apopto-
sis rate (Figure 8B). Since the loss of PARP1 in HeLa cells
led to a significant sensitization towards CPT treatment,
we examined if PARP1-reconstitution could rescue this ef-
fect. Indeed, when treating cells with increasing doses of
CPT two days prior to analysis, PARP1\WT reconstitution
could significantly rescue the sensitization effect observed
in PARP1 KO cells (Figure 8A). Interestingly, neither re-
constitution with PARP1\E988K nor with PARP1\L713F
were able to rescue the PARP1 KO effect, indicating that
full PARP1 functionality is necessary to protect cells from
CPT-induced genotoxic stress. Furthermore, CPT-induced
cell death could be mostly attributed to the induction of
necrotic cell death, while apoptosis was only slightly in-
duced in PARP1\WT and PARP1\E988K-reconstituted
cells and stayed at a constant high level in PARP1\L713F-
reconstituted cells (Figure 8A). Consistent with these re-
sults, treatment of PARP1-reconstituted cells with CPT in
the low nM range, led to a G2 arrest for all three vari-
ants, but with the highest proportion for PARP1\E988K-
reconstituted cells (Figure 8C).
It has been reported that PAR could induce the release of
apoptosis inducing factor (AIF) frommitochondria and in-
duce apoptosis via a pathway called parthanatos (65,66). To
examine whether this mechanism contributes to cell death
in unchallenged PARP1\L713F-reconstituted cells, we used
immunofluorescence confocal microscopy to analyze sub-
cellular AIF distribution. Although cells reconstituted with
the PARP1\L713F variant exhibited changes in the non-
nuclear AIF distribution compared to PARP1\WT- recon-
stituted cells, no nuclear translocation of AIF has been ob-
served (Supplementary Figure S6). Although at this stage,
we cannot exclude that the amount of AIF in the nucleus
is below the technical detection limit, it is unlikely that
cell death triggered by PARP1\L713F expression is me-
diated by AIF translocation. Presumably, PARP1\L713F-
mediated cell death is a result of depletion of cellular
NAD+ pools (Figure 4F) or through inhibition of glycol-
ysis (67,68).
In summary, modulating PARylation metabolism led to
remarkable cellular consequences, such as higher apopto-
sis rates induced by increased basal PAR levels through ex-
pression of the constitutively active PARP1\L713Fmutant,
or severe effects on cell cycle progression by expression of
the mono/oligo(ADP-ribosyl) transferase PARP1\E988K.
Importantly, in both cases effects were mediated by enzy-
matic activities of the PARP1 mutants, since they could be
blocked by PARP inhibition.
Reconstitution of HeLa PARP1 knock-out cells with natural
PARP1 variants
In a second set of PARP1 variants, we analyzed two vari-
ants naturally occurring in humans, i.e. (i) the V762A poly-
morphic variant (valine to alanine exchange at aa position
762) (35). This variant displays reduced enzymatic activ-
ity in in vitro studies using rec. PARP1 (36,37) and is as-
sociated with higher risks for specific types of tumors in
certain ethnicities (38,39). To the best of our knowledge,
PARP1\V762A has not been characterized in detail in a
cellular environment. (ii) Using exome sequencing of pe-
ripheral blood DNA from a patient with pediatric colorec-
tal cancer, we identified the V762A polymorphism to co-
occur with a novel rare PARP1 mutation, i.e. a genomic
910T>Cmutation leading to a phenylalanine to leucine ex-
change at the protein level at aa position 304, i.e. F304L.
This mutation was maternally inherited. Importantly, al-
though not in the focus of the present study, the paternal
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family history of this patient was positive for breast and
ovarian cancer, which can be explained by an accompanying
pathogenic frameshift mutation c.2808 2811del (p.A938fs)
in the BRCA2 gene [MIM 600185]. This aberration was
found to be present in the proband as well. Predisposi-
tion to pediatric CRC in BRCA2 mutation carriers has not
been reported before, but germline biallelic BRCA2 muta-
tions cause Fanconi anemia, a condition that predisposes
to pediatric cancer (69). We therefore assessed this patient
for the presence of a second germline mutation in BRCA2,
which was not found. Subsequent whole exome sequenc-
ing revealed no de novo mutations, nor mutations affecting
both alleles of one gene. The c.910T>C (p.F304L) variant
in the PARP1 gene (Figure 9A), which was one of the rare
candidate pathogenic variants, was analyzed in more detail
in tumor tissue-derived DNA of this patient. Of the chro-
mosome 1q42.12 region, which harbors PARP1, two copies
were present, and SNP array data revealed no indication for
acquired uniparental disomy of this region in the tumor tis-
sue. After Sanger sequencing of PARP1 on tumor DNA no
second hit mutationwas found. The F304 residue of PARP1
is a highly conserved residue at the homodimer interface
within the third zinc-binding domain, which may be im-
portant for PARP1 dimerization and DNA-dependent en-
zyme activation (70). At present it is unclear if this PARP1
mutation may have contributed to colon carcinogenesis. To
address this hypothesis, we first examined if the F304L ex-
change disturbs PARP1 enzymatic activity. To this end, we
generatedmutantPARP1 cDNAs by site-directedmutagen-
esis, coding for either a phenylalanine or leucine at position
304 and either a valine or alanine at position 762. Activ-
ity testing of rec. proteins carrying the four different com-
binations was performed by a well-established biochem-
ical immuno-slot blot assay (Supplementary Figure S7).
This confirmed previous results showing that the V762A
exchange is associated with reduced PARP1 activity (Fig-
ure 9B). Importantly, the PARP1\F304L variant showed re-
duced PARP1 activity by about 50% compared to respective
WT, both in the absence and presence of the V762A poly-
morphism (Figure 9B). Of note, PARP1\F304L\V762A -
as found in the patient - exhibited only 30% of the maxi-
mum activity compared to PARP1\WT. These results indi-
cate that the presence of both the F304L and V762A amino
acid exchanges in PARP1 in the patient resulted in a cumu-
lative reduction in enzymatic activities.
Next, we analyzed the cellular properties of these two
natural PARP1 variants. This paves the way towards a
molecular risk assessment also of other natural occurring
PARP1 variants to assess the risk of carriers of these vari-
ants for disease development. Figure 9C shows that the en-
zymatic activities of the different natural PARP1 variants
behave very similar in a cellular environment compared to
the in vitro setting as shown in Figure 9B. Thus, when re-
constituting HeLa PARP1 KO cells with the different nat-
ural PARP1 variants, treating them with 50 M H2O2,
and subsequently analyzing their PAR forming ability via
immuno-epifluorescence microscopy, PAR formation was
reduced by ∼31% and ∼42% in cells reconstituted with the
PARP1\V762A and PARP1\F304L variants, respectively
(Figure 9C). Strikingly, under those conditions the activ-
ity of the PARP1\V762A\F304L variant declined by∼57%
Figure 9. Biochemical and cellular characteristics of natural PARP1 vari-
ants. (A) An inherited PARP1 mutation identified by exome sequencing
in a patient with pediatric colorectal cancer. The panel on the left shows
a subset of the sequencing reads spanning the individual mutations (data
based on hg19); the panel on the right shows the validation by Sanger se-
quencing in the child and the maternal samples to indicate the mode of
inheritance. Position of the mutation is indicated by red arrows. (B) Bio-
chemical characterization of natural PARP1 variants as used in this study.
Rec. enzymes were expressed in the Sf9/baculovirus system and purified
via size exclusion and affinity chromatography. PARP1 activity was exam-
ined by incubating 5 nM PARP1 with increasing concentrations of NAD+
as indicated in a reaction mixture as described in material and methods
section. Afterward, 15% of reaction mixtures were slot-blotted on a nylon
membrane (see Supplementary Figure S7) and PAR content was analyzed
by immunochemical staining using the 10H antibody.Means of n= 3 inde-
pendent experiments. A non-linear Michaelis-Menten model was used for
curve fit. Statistical analysis using 2-way ANOVA testing. (C) Analysis of
intracellular PARP1 activity inPARP1KO cells reconstituted with PARP1
variants as indicated 2 days after transfection by immuno-epifluorescence
microscopy as shown in Figure 4 (for representative raw data refer to Sup-
plementary Figure S7). Cells were treated with H2O2 for 5 min in concen-
trations as indicated, and PAR levels of eGFP-positive cells were examined
using the anti-PAR-specific mAB 10H. Means ± SEM of n = 5 indepen-
dent experiments. Statistical analysis was performed using matched two-
way ANOVA testing and Sidak’s post-test. (D) Time-course analysis of
PAR formation in PARP1-reconstituted cells after treatment of cells with
250 M H2O2. Means ± SEM of n = 4 independent experiments (>100
cells per experiment). Statistical analysis using matched two-way ANOVA
testing and Sidak’s post-test. (E) NAD+ levels in WT, PARP1 KO and
PARP1-reconstituted cells ± H2O2 treatment for 7 min as evaluated by
an enzymatic NAD+ cycling assay. Means ± SEM of n = 3 independent
experiments. Statistical analysis was performed via 2-way ANOVA testing
and Sidak’s post-test. (F) Recruitment and dissociation kinetics of natural
PARP1 variants at sites of laser-induced DNA damage. For representative
raw data refer to Supplementary Figure S7. Means ± SEM. Evaluation
from≥35 cells from three independent experiments. Statistical analysis was
performed using two-way ANOVA testing and Sidak’s post-test.
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compared to PARP1\WT. Treatment of cells with higher
doses of H2O2 (500 M) resulted in more moderate differ-
ences in PAR formation, with a ∼20%-reduced PAR for-
mation for the PARP1\V762A\F304L variant compared
to PARP1\WT (Figure 9C). This indicates that the maxi-
mum PAR forming ability in a cellular environment is sim-
ilar for the different variants, since under such treatment
conditions with high concentrations of H2O2, the PAR for-
mation in the cellular system is already saturated (Supple-
mentary Figure S3). Consistent with results from the dose-
response analysis, also time-course studies revealed reduced
activities for the PARP1\V762A and the PARP1\F304L
variants (Figure 9D). NAD+ levels in cells reconstituted
with the different natural PARP1 variants revealed no dif-
ferences under non-stress conditions and only minor differ-
ences after challenging cells with H2O2 (Figure 9E). This
suggests that PARP1 variants still keep their NAD+ hy-
drolyzing (NADase) function (71) active, which is con-
sistent with the findings of similar Km values of the dif-
ferent variants (Figure 3B). In a next step, we tested if
the aa exchanges of the natural PARP1 variants influ-
ence their localization dynamics at sites of DNA dam-
age by monitoring the localization of fluorescently labeled
PARP1 variants at site of laser irradiation as described
above (Figure 9F and Supplementary Figure S8). Inter-
estingly, PARP1\WT-reconstituted cells that were treated
with ABT888 shortly before irradiation, behaved similarly
to the PARP1\E988K mutant, i.e. reduced maximum lev-
els of recruitment, but longer persistence at the site of the
damage (Figure 5B). When analyzing cells reconstituted
with the different natural PARP1 variants, it became evi-
dent that all variants showed strongly reduced recruitment
to sites of laser damage with the strongest effects observed
for the PARP1\V762A\F304L variant (Figure 9F and Sup-
plementary Figure S8). Interestingly, while the maximum
protein levels at sites of laser damage were quite similar for
both the PARP1\V762A and the PARP1\F304L variant,
the dissociation behavior was significantly different, since
the PARP1\V762A variant persisted longer at sites of laser-
damage than PARP1\F304L.
In summary, we have identified a novel PARP1 mutant
(i.e. PARP1\F304L\V762A) in a patient with pediatric col-
orectal carcinoma and provide a biochemical character-
ization of enzymatic properties of this variant. Further-
more, cellular analyses of PARP1\F304L, PARP1\V762A,
PARP1\F304L\V762A revealed significant alterations in
their enzymatic activities and localization dynamics at sites
of DNA damage that might contribute to a higher risk of
disease development.
DISCUSSION
There is a lack of systems with a complete genetic dele-
tion of PARP1 in a human setting. Recently, gene edit-
ing technologies have become commonly available, such as
TALEN or CRISPR/Cas technologies, which allow genetic
modification in human cancer cell lines. Here we used the
TALEN technology to generate a complete genetic deletion
ofPARP1 in one of themost widely used human cell culture
systems, i.e. HeLa cells. We comprehensively characterized
such HeLa PARP1 KO cells with regards to their PARy-
lation metabolism and stress response phenotype. Further-
more, we used this system to test a spectrum of artificial and
natural human PARP1 variants in a cellular environment
without interference of endogenously expressed PARP1 to
improve our understanding on the cellular biochemistry
and functions of PARP1.
HeLa PARP1 KO cells did not express detectable levels
of PARP1 nor did they reveal any H2O2-induced PARP ac-
tivity, when analyzing intracellular NAD+ levels or using
the 10H antibody in immunofluorescence microscopy (Fig-
ure 1). This suggests that in HeLa cells, PARP1 is respon-
sible for most of the genotoxic stress-induced PARylation
and that PARP2 only plays a minor role in this cell type.
Ame et al. showed that 3T3 fibroblasts derived from Parp1
KO mice still produce significant amounts of PAR after
H2O2 treatment (as evaluated by 10H-immunofluorescence
microscopy), which led to the discovery of Parp2 (72). Us-
ing highly sensitive isotope dilution LC–MS/MS (20), we
did indeed observe low-level induction of PARylation upon
H2O2 treatment (Figure 1), which is consistent with the no-
tion that PARP2 can in part compensate the loss of PARP1
also in HeLa cells. Strikingly, basal levels of PAR were not
affected at all in HeLa PARP1KO cells, demonstrating that
under unstressed conditions other PARPs can fully com-
pensate for the loss of PARP1 (Figure 1). Our functional
analysis revealed that HeLa PARP1 KO cells showed re-
duced proliferation rates and were more sensitive towards
the treatment with H2O2 and CPT (Figure 2), thereby con-
firming the central role of PARP1 in genotoxic stress re-
sponse as previously reported from mouse models, PARP
inhibitor, and RNAi studies (73).
Reconstitution studies with the PARP1\E988K mutant
verified previous results that this variant acts as a mono-
or oligo-(ADP-ribosyl)transferase (Figure 4) (37,53,54). In
addition, with regards to its recruitment and release kinet-
ics at sites of laser-induced DNA damage, our results re-
vealed that the PARP1\E988K variant behaves similar in a
human cellular system as it does in a mouse system (Fig-
ure 5) (55). Thus, as observed by Mortusewicz et al., the
PARP1\E988K mutant showed impaired recruitment, yet
longer persistence, at sites of DNA damage. Generally, it is
thought that localization of PARP1 at sites of DNA dam-
age is regulated by its automodification status, since the
presence of the highly negatively charged PAR molecules
covalently attached to PARP1 may lead to electrostatic
repulsion of PARP1 from negatively charged DNA (74).
Our study extended this view by postulating the possibility
that non-covalent interaction of PARP1 with PAR via two
newly-identified putative PAR binding motifs (PBM1/2)
can act as a complementary mechanism in the regulation
of the PARP1-DNA interaction (Figure 6). Our finding
that PAR inhibits the PARP1-DNA interaction is in agree-
ment with the fact that PBM1 is located in ZnF2, which is
necessary for PARP1 binding to DNA strand breaks (5),
and that the PBM2 is located at the ZnF3–ZnF1 inter-
face (75). Nevertheless, recruitment studies, showing that a
PARP1\PBM mutant exhibits faster release kinetics from
sites of DNA damage (data not shown), point to a com-
plex spatio-temporal interplay between PARP1, DNA and
PAR. Furthermore, as pointed out by Huambachano et al.
and Chapman et al., additional PAR binding may occur
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via non-classical binding motifs, as identified by these au-
thors (18,62), adding another level of complexity. The anal-
ysis and functional relevance of the PARP1–PAR interac-
tion therefore warrants further evaluation.
The impaired recruitment of the PARP1\E988K mu-
tant to DNA damage suggests that initial PAR formation
at the site of DNA damage is necessary for subsequent
second-wave recruitment of PARP1 molecules (55). In ac-
cordance with this, results by Mortusewicz et al. show that
DNA-binding deficient PARP1 mutants still recruited to
sites of laser-induced damage in MEFs and that this re-
cruitment could be inhibited by PARP inhibitor treatment
(55). Consistent with our cytotoxicity and cell cycle anal-
yses of CPT-treated, PARP1\E988K-reconstituted HeLa
cells (Figures 7 and 8), previous results showed that the
PARP1\E988K reconstitution sensitized Parp1 KO MEFs
to CPT treatment in a colony formation assay (51). On the
one hand, it is tempting to speculate that these effects can
presumably be attributed to trapping of the E988K mu-
tant at sites of DNA damage and therefore manifesting
the damage (76). On the other hand, our finding showing
that PARP1\E988K expression by itself leads to a G2 ar-
rest, which goes along with higher NAD+ levels per cell
and increased nuclei sizes (Figures 4, 7 and 8), is proba-
bly unrelated to a potential trapping effect, since PARP
inhibitor treatment completely abolished these effects. In
agreement with this, we observed that increased H2A.X
and phospho-RPA2 levels in PARP1\E988K-reconstituted
cells can be rescued by PARP inhibitor treatment (Fig-
ure 7), suggesting that PARP1\E988K enzymatic activity
is able to induce replicative stress. This remarkable pos-
sibility suggests that PARP1-mediated mono/oligo-ADP-
ribosylation, which may occur upon certain stimuli or as
intermediates in PAR catabolism, exerts pronounced and
distinct cellular functions.
The PARP1\L713F mutant was originally described as a
gain-of-function variant with an over nine times increased
Kcat, but similar Km value compared to PARP1\WT (56).
These results were recently extended by a biochemical study
from Langelier et al. These authors demonstrated that the
L713F exchange in the hydrophobic core domain (HD)
of the catalytic domain (CAT) mimics the effect of DNA
damage-induced HD distortions, increasing PARP1 DNA-
independent activity up to ∼20-fold and elevating the cat-
alytic efficiency of PARylation while not affecting affin-
ity for NAD+ (3,57). The HD hydrophobic core mutants
studied by Langelier et al. did not show an increased level
of DNA-dependent activity compared to PARP1\WT, in-
dicating that these mutants act through the same mecha-
nism as DNA to stimulate PARP1 catalytic activity. Our
results revealed that the L713F mutant is constitutively ac-
tive in a cellular environment leading to elevated PAR levels
within cells, even without exogenously-induced DNA dam-
age (Figure 4). Thus, PARP1\L713F-reconstituted cells
represent a valuable tool to analyze cellular consequences of
PAR overproduction with or without application of geno-
toxic stress. In this regard, our experiments provide first evi-
dence that PAR overproduction or NAD+ depletion signifi-
cantly affects cell viability, since PARP1\L713F expression
drove cells directly into apoptosis, even without DNA dam-
age induction (Figure 8).
Since PARP1-dependent cell death has implications in
several neurodegenerative and neuroinflammatory diseases,
such as Parkinson’s disease and ischemia reperfusion dam-
age (77), the PARP1\L713F mutant can be very useful to
study mechanisms of disease related to PAR overproduc-
tion in a cellular setting.
Apart from studying the cellular biochemistry of PARP1
and molecular mechanisms of PARylation, the cell cul-
ture model reported in this study can be used to ana-
lyze structure–function relationships of naturally occurring
PARP1 variants. One of such variants that has been exten-
sively studied in recent years is a SNP in the PARP1 gene
leading to the V762A aa exchange (35). This variant has
been associated with an increased risk for gastric, cervi-
cal, and lung cancers and a generally increased cancer risk
in the Asian population, while being associated with a de-
creased risk for brain tumors (38,39). Consistent with the
notion that changes in PARP activity might be responsible
for these correlations, previous results revealed a reduced
enzymatic activity of the PARP1\V762A variant on the bio-
chemical level (36,37). On the other hand, studies of hu-
man cells derived of V762A carriers revealed inconsistent
results, with one study observing a gene-dose-dependent
reduction of PARP activity (78), whereas another one did
not find such an effect (79). Our results from reconstituted
HeLa PARP1 KO cells provide clear proof for decreased
activity of PARP1\V762A in a cellular environment under
conditions of genotoxic stress (Figure 9), thereby strongly
supporting a causative link for the increased tumor risk in
V762A carriers due to reduced PARP1 activity.
In a patient with pediatric CRC, who inherited a
frameshift mutation in BRCA2 from his father, we iden-
tified a maternally inherited missense variant in PARP1
(F304L) combined with the V762A polymorphism, which
significantly reduced PARP1 activity on the biochemical
and cellular level. Furthermore, the PARP1\F304L\V762A
mutant showed reduced recruitment efficiency to sites of
laser-induced DNA damage (Figure 9). The tumor in the
CRC patient was deficient for BRCA2 due to an inherited
pathogenic mutation in one allele and an acquired somatic
loss of the second wild-type allele. This functional loss of
both BRCA2 alleles, in conjunction with the inherited het-
erozygous PARP1 variant, may have resulted in an increase
in genomic instability and, as a consequence, early-onset of
cancer development in the colon. Interestingly, a very re-
cent study by Ding et al. demonstrated that pharmacolog-
ical PARP inhibition or PARP1-silencing in heterozygous
Brca2−/+ mESC resulted in viable homozygous Brca2−/−
mESC by loss of heterozygosity, a phenomenom termed
synthetic viability (80). This genetic constellation verymuch
resembles the one observed in the patient described in the
current study. Thus, the drastic impairment of PARP1 activ-
ity due to the cumulative effect of the F304L variant and the
V762Apolymorphism in combinationwith theBRCA2mu-
tation, may well have resulted in predisposition for CCRC
development in this patient, however this needs to be clari-
fied in detailed follow-up experiments. Reports on digenic
inheritance with germline mutations in genes with syner-
gistic interactions are scarce. This mode of inheritance has
been described in patients with extreme phenotypes, i.e. ex-
ceptionally early ages of onset or severe clinical presenta-
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tions. Examples of these are digenic inheritance in early on-
set Parkinson’s disease [MIM 605909] and severe insulin
resistance [MIM 125853] (81,82). On the other hand, in
cells deficient in PARylation activity, single-stranded (ss)
DNA breaks can accumulate, which, when encountered
during DNA replication, may result in the accumulation of
double-stranded (ds) DNA breaks. These dsDNA breaks
are repaired via HR, which requires proper functioning
of BRCA2. Therefore, following the concept of synthetic
lethality, cells that are deficient in BRCA2 are highly sensi-
tive to PARP1 inhibition, resulting in cell death by apopto-
sis (83,84). Thus, complete loss of PARP1 through a second
hit in the tumormost likely would have resulted in cell death
due to synthetic lethality. Therefore, in retrospect, this pa-
tient might have benefited from a PARP1 inhibitor therapy.
In conclusion, this study establishes a novel human cell
culture model to decipher the role of PARP1 and PARy-
lation in cellular functions, i.e. a complete PARP1 KO in
HeLa cells. Reconstitution with different PARP1 variants
enabled us to study PARP1 hypomorphy (E988K) as well
as hypermorphy (F713L) in an easy to handle and excep-
tionally well-characterized human cancer cell line. Further-
more, we used this approach to correlate epidemiological
and clinical findings on naturally occurring PARP1 variants
with the cellular properties of these variants. This provides a
basis for molecular risk assessment of these and other natu-
rally occurring PARP1 variants in order to judge if carriers
may be predisposed to the development of certain diseases.
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